Presents Positive

Related by string. * pre sented . presenter . presents . Presented . presenting : Present Situation Index . Top Gear presenter . Christmas Past Present . Kentucky Derby Presented . Alfred Hitchcock Presents / Positives . POSITIVE . positives . POSITIVES : Rating Watch Positive . retrieve false positives . tested positive . estrogen receptor positive * Presents Positive Preclinical *

Related by context. All words. (Click for frequent words.) 88 Completes Patient Enrollment 87 Initiates Phase II 87 Presents Positive Preclinical 86 Completes Enrollment 86 Presents Preclinical 86 Initiates Clinical Trial 86 Reveals Positive 85 Initiates Phase III 85 Receives Milestone Payment 85 Initiates Enrollment 85 Receives Orphan Drug Designation 84 Begins Dosing 84 Presents Preclinical Data 84 Phase 2b Clinical Trial 84 Initiates Clinical 83 Receives Approvable Letter 83 Therapeutic Competitors Companies 83 Meets Primary Endpoint 83 Files IND 82 Successfully Completes Phase 82 Clinical Trial Results 82 Commences Phase 82 Enrolls First 82 Submits NDA 82 Initiates Phase 82 Announces Presentation 81 Drug Candidate 81 Collaborators Present 81 Phase IIb Clinical Trial 81 Announces Positive 81 Submits Biologics License Application 81 Demonstrates Positive 81 Announces Initiation 81 Reports Preclinical Data 81 Initiates Dosing 81 Cites Positive 81 Submits IND 80 Reports Positive 80 Receives Orphan Drug 80 Receives Fast Track 80 Preclinical Data 80 Licenses Novel 80 Pivotal Phase III 80 FDA Accepts 80 Present Preclinical Data 80 Investigational Compound 80 Submits Response 80 Phase IIb Trial 80 Completes Dosing 80 Granted Orphan Drug 79 Demonstrates Significant 79 Phase IIa Clinical Trial 79 FDA Clears 79 Phase III Clinical Trial 79 Earns Milestone Payment 79 Patient Enrollment 79 Initiate Phase 79 Oral Calcitonin 79 Announce License Agreement 79 Therapeutic Competitors companiesandmarkets.com adEgemonye 79 Announces Poster Presentations 79 Phase 2b Trial 79 PRN FDA Approves 79 Inc Therapeutic Competitors 79 JAK2 Inhibitor 78 Study Evaluating 78 Phase III Trial 78 Combination REOLYSIN R 78 Shows Promising 78 Receives FDA Clearance 78 Announces Publication 78 Achieves Primary Endpoint 78 Drug Fails 78 Phase 2a Trial 78 Vaccine Adjuvant 77 Submits Supplemental 77 Initiates Clinical Trials 77 Receives Complete Response 77 Inc. Nasdaq OXGN 77 Initiates Phase 2b 77 Collaborators Publish 77 Gets FDA Clearance 77 pralatrexate injection folate analogue 77 Pivotal Phase 77 Trial Evaluating 77 Novel Oral 77 BioSante Pharmaceuticals Announces 77 Receive Milestone Payment 77 Announces Tentative Approval 77 Files Investigational 77 Mylan Receives Approval 77 Announces FDA Clearance 77 Announce Initiation 77 Announce Collaboration Agreement 76 Previously Treated 76 Clinical Trial Evaluating 76 NDA Submission 76 Investigational Oral 76 FOLOTYN ® 76 Completes Patient Enrolment 76 Pivotal Study 76 Significantly Improves 76 Protease Inhibitor 76 Develop Novel 76 Investigational Treatment 76 Lupus Drug 76 Prolongs Survival 76 Initiate Clinical Trial 76 Receives Positive 76 Initiate Phase III 76 Patients Treated With 76 Kinase Inhibitor 76 Announces Dosing 75 R MSCRAMM 75 Spectrum Pharmaceuticals Announces 75 Milestone Payment 75 Improves Survival 75 Receives NASDAQ 75 Announce Merger Agreement 75 Sign Licensing Agreement 75 Hsp# Inhibitor 75 FDA Approvals 75 Receives Tentative Approval 75 FDA Approves 75 Immunomedics Announces 75 First Patient Enrolled 75 IG HCR ;) CO 75 Drug Shows Promise 75 Phase 2a Clinical Trial 75 II Clinical Trial 75 Commences Phase III 75 Namenda Memantine HCl 75 Sign License Agreement 75 VIVUS Announces 75 FDA Okays 75 IND Application 75 Jumps Higher 75 Osteoporosis Drug 75 Migraine Drug 74 Files Shelf Registration Statement 74 Receives Favorable 74 Adjunctive Therapy 74 Significantly Reduces 74 Randomized Phase 74 Novartis Novo Nordisk 74 Announce Licensing Agreement 74 Improves Outcomes 74 Commence Phase 74 Awarded Qualifying Therapeutic 74 Systemic Delivery 74 Receives Positive Opinion 74 Shows Efficacy 74 Gout Drug 74 Receives Patent 74 RNAi Therapeutic 74 Antitumor Activity 74 Sangamo BioSciences Announces 74 Single Dose 74 Oral Fingolimod 74 HCV Protease Inhibitor 74 MBRX 74 estrogen receptor beta agonist 74 Pooled Analysis 74 Arthritis Drug 74 please visit http:/www.vandapharma.com 74 Tezampanel 74 Nasdaq PGNX 74 Anti Tumor 74 Submits Application 74 non nucleoside inhibitor 74 Telik logo TELINTRA 74 Orally Active 74 Anti Tumor Activity 74 Crofelemer budesonide foam 74 Brentuximab Vedotin SGN 74 Shows Promise Against 73 Lung Cancer Drug 73 Severe Sepsis 73 Chronic Hepatitis C 73 Novel Antibiotic 73 Shows Promise 73 Rheumatoid Arthritis Drug 73 Study Demonstrates 73 Therapeutic Competitors Report 73 Therapeutic Competitors 73 Launches Generic Version 73 Advanced Melanoma 73 Investigational Drug 73 Xcytrin R 73 Randomized Phase II 73 Preclinical Study 73 Taro Receives 73 Phase 2a Study 73 Inflammatory Arthritis 73 Phase 2b Study 73 Demonstrates Potential 73 Metastatic Melanoma 73 Pivotal Trial 73 Corp. AMEX CVM 73 Sinks Lower 73 By JENNIFER LEARN 73 IND Filing 73 Vitrasert R 73 Refractory Hodgkin Lymphoma 73 Achieves Milestone 73 Psoriasis Drug 73 FDA APPROVES 73 Phase 1b Clinical Trial 73 Patent Covering 73 please visit http:/www.atherogenics.com 73 Genentech sanofi aventis 73 Demonstrates Sustained 73 Nasdaq XTLB 73 Vicriviroc 73 TO AVOID PREGNANCY WHILE 73 TRACON Pharmaceuticals 73 Pegloticase 73 Demonstrates Potent 73 Recombinant Human 73 Dose Ranging Study 73 Pharma Merck Serono 73 Tyrosine Kinase Inhibitor 73 Fast Track Status 73 Study Showed 73 Amends Agreement 73 Nasdaq EPCT 73 Romidepsin 73 REG1 Anticoagulation System 73 Q3 Loss Widens 73 Q2 Loss Narrows 73 Transdermal Patch 73 OTC BB PVCT 73 RNAi Therapeutics 73 Demonstrates Statistically Significant 73 Newly Diagnosed Multiple Myeloma 73 Q1 Loss Narrows 72 Inc. www.micromet inc.com 72 Invites Investors 72 Extends Collaboration 72 Well Tolerated 72 Schizophrenia Drug 72 Humanized Anti 72 Desvenlafaxine Succinate 72 Potent Antiviral Activity 72 Topline Results 72 novel orally inhaled 72 Effectively Treats 72 markets HP Acthar 72 Announces Licensing Agreement 72 Epilepsy Drug 72 Begins Clinical Trial 72 Announces License Agreement 72 Sapacitabine 72 Q4 Loss Narrows 72 Merck OSI Pharmaceuticals 72 Q4 Loss Widens 72 Reacquires 72 developing ACAPODENE 72 Lanthanum Carbonate 72 5q MDS 72 Provides Update Regarding 72 Confirms Efficacy 72 platform HDL Mimetic 72 pan histone deacetylase 72 Prostate Cancer Vaccine 72 First Patient Treated 72 Obtains FDA 72 Announces Successful Completion 72 Biogen Genentech 72 Demonstrates Efficacy 72 Long Term Efficacy 72 Demonstrated Significant 72 Nicotine Vaccine 72 dependent kinase inhibitor 72 Patent Issued 72 Awarded Patents 72 visit www.genenews.com 72 NASDAQ ADLR 72 Pruvel TM 72 Adjuvant Treatment 72 Identifies Potential 72 By JAMAAL ABDUL 72 Hematological Malignancies 72 Vascular Disrupting Agent 72 Nasdaq HALO 72 initiated Phase Ib 72 Receives Regulatory 72 Q3 Loss Narrows 72 Agonist MABA program 72 Submits Investigational 72 Flamel Technologies Announces 72 includes TOLAMBA TM 72 combines bupropion 72 candidates Azedra TM 72 Lupus Nephritis 72 Personalized Immunotherapy 72 Small Molecule 72 Ovitrelle R Serostim 72 Receptor Antagonist 72 Antibody Drug Conjugate 72 markets COLAZAL 72 Complicated Skin 72 Obtains License 72 Begins Shipment 72 essential thrombocythemia ET 72 Receives CE Marking 72 Q2 Loss Widens 72 Receives SFDA Approval 72 Inc. ProMetic www.prometic.com 71 Nasdaq VNDA 71 Preclinical Models 71 MEK Inhibitor 71 Regains NASDAQ 71 Phase III Trials 71 Nasdaq MNKD focuses 71 Acquires Exclusive 71 Develops Novel 71 Cholesterol Lowering Drug 71 Therapeutic Antibody 71 TRANSDUR ® 71 Generic Version 71 Grants Orphan Drug 71 THERAPEUTICS 71 programs visit http:/www.bionovo.com 71 CysDisplay R 71 Teva Provides Update 71 TM Aganocide 71 Biopharmaceuticals AG 71 Taglich Brothers Initiates Coverage 71 Genentech Wyeth Pharmaceuticals 71 Elagolix 71 Immunotherapeutic 71 vapreotide acetate 71 TELINTRA R 71 Genentech GlaxoSmithKline 71 lead molecular radiotherapeutic 71 Boehringer Ingelheim MedImmune 71 PPD Declares 71 developing Bicifadine serotonin 71 Net Loss Narrows 71 R Saizen R 71 Tech DVAX 71 Combination Treatment 71 NASDAQ ENMD 71 Phase III Pivotal 71 Multiple Ascending Dose 71 Disease Modifying 71 Controlled Study 71 Reduces Risk 71 pharmacogenomic translational research 71 Dose Escalation 71 Plaque Psoriasis 71 Nasdaq DVAX 71 Expand Collaboration 71 Nasdaq CTIC 71 R lenalidomide 71 Shareholders Approve Acquisition 71 AAG geldanamycin analog 71 Safinamide 71 Files Patent Application 71 Provides Detailed 71 Million Milestone Payment 71 Hormone Refractory Prostate Cancer 71 Announces Favorable 71 SIX RO ROG 71 Cholesterol Drug 71 Provides Preliminary 71 Randomized Double Blind 71 Pharmaceuticals Initiates 71 Obtains Exclusive License 71 Licenses Patents 71 Efficacy Results 71 AUDIO PROVIDED BY 71 Double Blind Placebo 71 Demonstrate Significant 71 Alvine Pharmaceuticals 71 Report companiesandmarkets.com adds 71 JAK Inhibitor 71 Anti Inflammatory 71 sapropterin dihydrochloride 71 Polymerase Inhibitor 71 Pharmacyclics Announces 71 Dose Finding 71 Demonstrates Ability 71 Dose Ranging 71 Vitro Activity 71 Significantly Improved 71 Monotherapy 71 R memantine HCl 71 evaluating picoplatin 71 INSPIRE Trial Phase III 71 Signs Licensing Agreement 71 OTCBB FCSC 71 Acute Attacks 71 VIVITROL ® 71 Controlled Trial 71 BIOTECHNOLOGY SOURCE 71 Shows Statistically Significant 71 Ltd Therapeutic Competitors 71 Announces Issuance 71 Novartis Organon 71 Completes Merger With 71 Inc SPPI 71 Nasdaq AVNC 71 Provides Guidance 71 Mg Usa 70 OTCBB IMUC 70 Clinical Efficacy 70 Reports Receipt 70 Pafuramidine 70 Patients Receiving 70 Calls Purchased 70 HDAC Inhibitor 70 Diabetic Foot Ulcer 70 R roscovitine CDK cyclin 70 ATRA IV 70 highly purified pasteurized 70 Confirmatory Phase 70 Successfully Treated 70 Treatment Experienced 70 Cutaneous T 70 Novel Therapeutic 70 Pivotal Clinical Trial 70 Awarded Patent 70 SPRYCEL ® 70 Data Suggest 70 Treatment Naïve 70 NicVAX TM 70 Aztreonam Lysine 70 visit www.sciclone.com 70 VentiRx Pharmaceuticals 70 Relapsing Multiple Sclerosis 70 Anticancer Compound 70 Receives Notification 70 Settle Patent Litigation 70 Anticancer Agent 70 investigational oral inhibitor 70 Regains Full 70 hyaluronidase enzyme 70 Placebo Controlled Trial 70 Parathyroid Hormone 70 TKB# 70 Treatment Resistant 70 Board Authorizes 70 please visit http:/www.supergen.com 70 Generic Versions 70 Receives Unsolicited 70 Systemic Sclerosis 70 GVAX ® 70 Regains Compliance With 70 Obtains Approval 70 Abstract Accepted 70 Staphylococcus aureus Immune Globulin 70 Monoclonal Antibody 70 methylnaltrexone bromide 70 Aeolus Pharmaceuticals Announces 70 proprietary intravenous formulation 70 developing Zerenex ferric 70 Statistically Significant 70 Testosterone MDTS ® 70 Anti CD# Antibody 70 Expands Scientific Advisory 70 Announces Dismissal 70 Pivotal Trials 70 Welcomes Analyst Initiation 70 oral prodrug 70 Bullish Average Crossover 70 Successfully Completes Tender Offer 70 acetonide FA 70 otcstockexchange.com 70 Introduces Novel 70 visit http:/www.mannkindcorp.com 70 novel emulsion formulation 70 novel proprietary KL4 70 Randomized Trials 70 diarrhea fatigue asthenia 70 Voluntarily Withdraws 70 Nasdaq PARD 70 Pharmacokinetic Study 70 Corp. NASDAQ CYTR 70 Commercialize Novel 70 bone marrow reticulin deposition 70 Amigal TM 70 Issued Patent 70 Jointly Announce 70 markets Testim ® 70 Novel Mechanism 70 First Patient Dosed 70 XL# anticancer compounds 70 Q1 Loss Widens 70 Nasdaq AEGR 70 Cypher Sirolimus 70 Luveris R Ovidrel R 70 ® adefovir dipivoxil 70 Hedgehog Pathway Inhibitor 70 Relapsed Refractory 70 Patients Suffering 70 Preclinical Efficacy 70 novel MetAP 2 70 Proves Effective 70 Diabetic Neuropathy 70 Vaccine Protects Against 70 Merck Serono Nycomed 70 Inc. Nasdaq IMGN 70 IN PATIENTS WITH 70 Ragweed Allergy 70 Unanimously Recommends Approval 70 VEGFR2 inhibitor 70 Expanded Indication 70 Bradmer Pharmaceuticals 70 Patient Enrolment 70 ASE SVA 70 Maven Semantic 70 Phase Ib Clinical Trial 70 includes Dideco CarboMedics 70 Biomarker Study 70 developing adecatumumab 70 Provides Comprehensive 70 Achieves Positive 70 Signs License Agreement 70 Receives Approvals 70 visit www.targanta.com 70 Terminate Merger Agreement 70 Nasdaq IDIX 70 Anticancer Activity 70 Is Well Tolerated 70 INDICATED LOWER 70 TRANSDUR ™ 70 Randomized Double Blind Placebo 70 GTC NASDAQ GTCB 70 4SC AG ISIN DE# 70 MKC# MT 70 PRESENTED AT 70 Relapsed Multiple Myeloma 70 ALN HPN 70 Secures Financing 70 Mouse Model 70 developing ostarine selective 70 Treating Chronic 70 Milestone Payments 70 Receptor Agonist 70 Randomized Double blind 70 Oral Formulation 70 Amex PTN 70 Net Loss Widens 70 Nicotine Conjugate Vaccine 70 Matrix Phase 2b 70 Novel Treatments 70 Veronate R 70 NOTE POSIDUR ™ 70 dihydrochloride Tablets 70 CYT# potent vascular disrupting 70 interferon beta 1a infertility 70 Platelet Inhibition 70 Telaprevir VX 70 sanofi aventis Bayer Schering 70 Patients Treated 70 corticotropin injection 70 PNP inhibitor 70 Nasdaq TARG 70 Settles Litigation 70 STERIS Corporation Announces 70 IL# PE#QQR 70 Novel Compound 70 humanized therapeutic 69 Recommends Approval 69 Pulmonary Arterial Hypertension 69 molecular imaging radiopharmaceutical 69 Voluntarily Withdraw 69 2 methoxyestradiol 69 Bullish Technical Alert 69 Trodusquemine MSI 69 Inhaled Liposomal Ciprofloxacin 69 Therapeutic Vaccine 69 CONTINUES LOWER 69 NASDAQ MNKD focuses 69 Alnylam Nasdaq ALNY 69 oral nucleoside analogue 69 Inc. NASDAQ SIRT 69 WeissComm Partners +#-#-#-# 69 OPXA 69 Transcept Pharmaceuticals 69 Board Unanimously Rejects 69 UGNE 69 CybeRelease Decliners 69 Benzinga Volume Movers 69 Blood Pressure Drug 69 particularly SANCTURA XR 69 Announce Collaboration 69 Surfactant Technology 69 OTCStockExchange.com Stock Alert 69 Telik Announces 69 gets USFDA nod 69 NASDAQ MIPI 69 Bristol Myers Squibb sanofi 69 Attenuates 69 Cypress Bioscience Inc 69 Late Breaker 69 RANK Ligand inhibitor 69 Detailed Product 69 albiglutide 69 Milestone Payment From 69 Previously Untreated 69 Bristol Myers Squibb Celgene 69 Inc. Nasdaq MITI 69 Clinical Evaluation 69 Reports Significantly Improved 69 Regains Compliance 69 SPL# Gel vaginal microbicide 69 telomerase therapeutic 69 OTC BB PVCT http:/www.pvct.com 69 Molecular Diagnostic Test 69 Begin Clinical Trials 69 NYSE Amex PBTH 69 Paris IPN Euronext 69 Kelly Luethje #-#-# 69 evaluating tivozanib 69 Receives Notice 69 Announces Postponement 69 Successful Completion 69 Exercises Option 69 Receives Favorable Ruling 69 Updates Shareholders 69 Oncology Compounds 69 Chronic Hepatitis B 69 Positive Results 69 Atypical Antipsychotic 69 derivatives Radilex TM 69 Announces Preliminary 69 Romiplostim 69 Attracting Bullish Investors 69 Identifies Key 69 Shown Effective 69 selectin antagonist 69 Improved Survival 69 Provides Updated 69 Sirolimus Eluting Stent 69 Multicenter Phase 69 submitted supplemental Biologics 69 Clinical Study 69 Second Pivotal Phase 69 Clinical Study Shows 69 PROVENGE ® 69 Plicera TM 69 NASDAQ IDRA 69 Medisorb ® 69 Announce Receipt 69 Schedules Fiscal 69 Early Relapsing Multiple 69 Receives Tentative FDA 69 Study Validates 69 Hematological Cancers 69 ® lenalidomide 69 Versus Placebo 69 Nasdaq ACAD 69 virus HCV protease inhibitor 69 Commercialize 69 Zorbtive TM 69 Patients Enrolled 69 Slow Progression 69 Rotavirus Vaccine 69 visit http:/www.PAREXEL.com 69 Study Shows Promise 69 Puts Purchased 69 Provides Shareholder 69 Clinical Trial Data 69 Increases Risk 69 Strengthens Balance Sheet 69 palonosetron hydrochloride Injection Dacogen 69 peptidic compound 69 Pancreas Cancer Vaccine 69 AVI BioPharma Announces 69 Explore Strategic Alternatives 69 Release Capsules 69 oncolytic virus therapies 69 Announces Commencement 69 including eniluracil ADH 69 researches develops licenses 69 Onyx Pharmaceuticals Announces 69 Study Indicates 69 Synthetic Peptide 69 Lowers Risk 69 Nasdaq ENMD 69 Nasdaq SMTS develops manufactures 69 ORADUR ® 69 Treatment Reduces 69 TSX LOR OTCBB LRUSF 69 Announces Adjournment 69 Restructures Operations 69 Cephalon GlaxoSmithKline 69 CD# CEA 69 refractory chronic lymphocytic 69 Receives Conditional 69 investigational humanized monoclonal antibody 69 R famotidine 69 CHEAP ONLINE PHARMACY LOW 69 Webcast Presentations 69 Announces Cancellation 69 COLLABORATION WITH 69 CRWEWallstreet.com Stock Report 69 Updates Guidance 69 Nasdaq IDEV 69 Enters Into Collaboration 69 Maribavir 69 Regenerative Cells 69 Perifosine KRX 69 Colaris Colaris AP 69 NYSE Amex YMI 69 Nasdaq IMGN 69 Skymark Research Initiates Independent 69 Reconfirms 69 Aflibercept 69 SABER ™ 69 Significantly Increases 69 ODT metoclopramide HCl PEPCID 69 Earnings Postmortem 69 Receives Clearance 69 Host Fourth Quarter 69 topical antifungal product 69 Inflammatory Diseases 69 PWRM.OB 69 Showed Significant 69 candidates Azedra 69 COMPLETES ACQUISITION OF 69 Kuvan R 69 Ondansetron Orally Disintegrating Tablets 69 FEMALES SHOULD BE ADVISED 69 Survival Benefit 69 NICE Recommends 69 Oral Laquinimod 69 please visit www.dyax.com 69 IMiDs ® 69 CRWESelect CRWESelect.com Highlights 69 please visit www.medicinova.com 69 Inhibits 69 Finalizes Acquisition 69 www.ucb group.com 69 Test Detects 69 NewsBite Downgrade Puts Pressure 69 AMEX KAL 69 Aradigm Logo 69 Bearish Speculation 69 Nasdaq PPHM clinical 69 Dyax logo 69 novel histone deacetylase 69 proprietary intranasal insulin 69 Postmenopausal Women 69 Updates Status 69 Secondary Hyperparathyroidism 69 Closes Previously Announced 69 Completes Tender Offer 69 Glatiramer Acetate 69 Moving Average Crossover Alert 69 Crit Rev 69 Gets Bearish Confirmation 69 markets XIFAXAN ® 69 Announces Effective Date 69 Signs Merger Agreement 68 Nuvelo Announces 68 developing Surfactant Replacement 68 Bearish Average Crossover 68 Postmenopausal Osteoporosis 68 Inc. OTCBB ECTE 68 Provides Updates 68 PFIZER INC. 68 MONSTERSTOX.COM Monsterstox.com 68 mGluR5 negative 68 Inhalation Aerosol 68 PEGylated Fab fragment 68 Downtrend Spotted 68 OTCBB GNTA 68 Inhaled Insulin 68 Testosterone MDTS R 68 Completes Financing 68 ENL recurrence 68 NYSE PFE Exelon Rivastigmine 68 product candidate Lpathomab 68 Exploit collaboration 68 Canaccord Genuity Maintains Hold 68 Issues Guidance 68 mGluR2 positive 68 Transgenomic Pharmacogenomics Services 68 Supplemental Biologics License Application 68 Successfully Completes Acquisition 68 THE TREND CONTINUES DOWN 68 ARRY # 68 Pharmacokinetics PK 68 Omacetaxine 68 www.ucb.com 68 VERTEX PHARMACEUTICALS 68 Gel repository corticotropin injection 68 Mg Uk 68 Bazedoxifene 68 NASDAQ XTLB 68 Announce Licensing 68 Benign Prostatic Hyperplasia 68 Guides Below 68 Declares Increase 68 Renal Cell Carcinoma 68 Forecast Quick Facts 68 NASDAQ AVNR 68 Treated Patients 68 evaluating mipomersen 68 Combination Therapy 68 Study Confirms 68 GATTEX TM 68 Subsidiary Enters 68 PharmaVitae Profile 68 CYP#A# CYP#D# 68 Bosutinib 68 FY# Loss Widens 68 ELADUR ™ 68 BIOSCIENCES 68 Nasdaq CYCC 68 Slows Progression 68 ALTROPANE R 68 interferon gamma 1b 68 Patient Dosing 68 Tumor Targeting 68 website www.celsion.com 68 Nasdaq SLXP 68 Tibotec BVBA 68 Drug Resistant 68 Hematology Molecular Pathology 68 Prospective Randomized 68 Safety Tolerability 68 NASH Huntington 68 Anemia Drug 68 Aurora Kinase 68 Kaydon Corporation Announces 68 Strengthens Position 68 Extend Collaboration 68 Enzon Pharmaceuticals Inc 68 balsalazide disodium Capsules 68 Shareholders Approve Merger 68 J.P. Morgan Healthcare 68 THE TREND CONTINUES LOWER 68 Secures Additional 68 Announces Termination 68 Bullish Speculation 68 Signs Agreements 68 Nasdaq OSIP 68 Novel Inhibitor 68 Webcast Discussion 68 NYSE Amex RNN 68 compound PMX # 68 Prophylactic Treatment 68 MCSP respectively 68 product platforms AZX# 68 Primary Hypercholesterolemia 68 Announces Stock Repurchase 68 Demonstrates Long Term 68 submitted Biologics License 68 lexidronam injection 68 EVIZON TM 68 SIGNING LOW OF 68 PSDV 68 Announcement acc 68 siRNA Delivery 68 topical gel formulation 68 Appoints Seasoned 68 widens Quick Facts 68 Nasdaq ZGEN 68 Capsules CII 68 Redhotpennystock.com Alert 68 ONYX PHARMACEUTICALS 68 SWOT Analysis Aarkstore Enterprise 68 DAY PATTERN FOR 68 Extends Tender Offer 68 Q1 Adj 68 COLAZAL R 68 Ozarelix 68 website http:/www.celsion.com 68 Announces Stockholder Approval 68 Significantly Expands 68 Nitazoxanide 68 Revises FY# Outlook 68 Naglazyme R 68 Trend Continues Down 68 Confirms Receipt 68 Nasdaq SGEN 68 Host Third Quarter 68 Inflammatory Disease 68 please visit www.abraxane.com 68 Helps Predict 68 MOVIPREP R 68 Meta Analysis 68 Chronic Lymphocytic Leukemia CLL 68 Chronic Myeloid Leukemia 68 Mutually Agree 68 evaluating bafetinib 68 Inc. NASDAQ QLTI 68 NASDAQ SHPGY 68 Posts Wider Loss 68 Successfully Completed 68 therapeutically inactive prodrug 68 OTCBB PYTO 68 PROLOR Biotech Inc. 68 Reports Profitable 68 Novel Vaccine 68 Explores Strategic Alternatives 68 Sign Definitive Merger 68 Finalizes Purchase 68 hyperphenylalaninemia HPA due 68 Reduces Mortality 68 Guides Inline 68 Q1 Profit Surges 68 Trastuzumab DM1 68 NRGN 68 LGND 68 TSX NVN 68 HER2 Positive 68 Hold Fourth Quarter 68 Elderly Patients 68 Locteron exclusively 68 Seliciclib CYC# 68 Nasdaq PHRM 68 KRYSTEXXA TM pegloticase 68 induced mucositis 68 Tramiprosate ALZHEMED TM 68 Exherin 68 ALN PCS 68 Phase III Clinical Trials 68 Receives CE 68 Announce Early Termination 68 Receives Commitment 68 Proven Effective 68 Nasal Powder 68 Guides FY# Quick Facts 68 Acute Exacerbations 68 Aethlon Medical Releases 68 METOZOLV TM ODT metoclopramide 68 Canaccord Genuity Reiterates Buy 68 Therapy Improves 68 Enteral Feed Devices 68 Ltd. OTCBB IMUC 68 Disease IBD 68 Company website www.anormed.com 68 Coverage Initiated 68 recurrent metastatic ovarian cancer 68 DARA logo 68 Takeda Kyowa Hakko Kirin 68 Hemodialysis Patients 68 Therapeutic Potential 68 Antisense Drug 68 Myelodysplastic Syndromes 68 Atripla combines 68 #-# Full Text 68 IMPDH inhibitor 68 Successfully Concludes 68 NASDAQ CRXL 68 Combo Therapy 68 myelodysplastic myeloproliferative diseases 68 Anticancer Drug 68 EntreMed Presents 68 Receives Anticipated 68 Rated Speculative Buy 68 Diabetic Nephropathy 68 COMUNICADO DE 68 Nasdaq ONXX 68 Visit www.BASInc.com 68 OTCBB GETA 68 Doripenem 68 Nasdaq SNSS 68 Bone Metastases 68 DVAX 68 Enters Into License Agreement 68 Treatment Naive Patients 68 Phase IIa Trial 68 Settle Patent Dispute 68 RELEASES ITS QUARTERLY NUMBERS 68 Restate Financial 68 Completes Previously Announced 68 Subtypes 68 dasatinib Sprycel ® 68 Phospholipase A2 68 Extended Release 68 NASDAQ VPHM 68 ® decitabine 68 OTCBB DORB 68 HCl PEPCID ® famotidine 68 topically applied SEPA 68 Nasdaq CYTX 68 molecular therapeutics immunotherapies 68 nephropathic cystinosis cystinosis 68 Completes Transaction 68 Announces Discontinuation 68 cetuximab Erbitux R 68 Circulating Tumor Cells 68 Naive Patients 68 J Allergy Clin 68 Hypertensive Patients 68 Ridaforolimus 68 novel antimitotic agent 68 CHEAP ONLINE PHARMACY BEST 68 Drug Combo 68 Terminates Agreement 68 Releases Second Quarter 67 signal detection CTSD

Back to home page